Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.